| 000 | 02266cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030713.0 | ||
| 008 | 121114s2012 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.23.Ph.D.2012.Wa.P | ||
| 100 | 0 | _aWael Mahmoud Youssef | |
| 245 | 1 | 0 |
_aPhase II prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA hodgkin lymphoma with role of prognostic biological parameters : _bA prospective hospital based study / _cWael Mahmoud Youssef ; Supervised Wafaa Hassan Elmetnawy , Farook Haggag , Emad Hamada |
| 246 | 1 | 5 | _aدراسة تجريبية اكلينيكية مقارنة لعلاج المراحل الأولى و الثانية و الثالثة أ من مرضى أورام الغدد الليمفاوية الهودجكين بالعلاج الكيميائي بعقارات الدوكسوروبسين و البليوميسين و الفينبلاستين و الداكاربازين يتبع بالعلاج الاشعاعى مقارنة بالعلاج الكيميائي فقط مع تقييم دور العلامات البيولوجية و تأثيرها على مسار المرض |
| 260 |
_aCairo : _bWael Mahmoud Youssef , _c2012 |
||
| 300 |
_a183 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology-Clinical | ||
| 520 | _aThe optimal treatment of early-stage hodgkin lymphoma has been controversial because of the success of several approaches. Concerns regarding radiation toxicities and the previously detected good response to chemotherapy have led some to withhold radiation therapy (RT) for the treatment of stage I, II and IIIA hodgkin's lymphoma | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aABVD | |
| 653 | 4 | _aBleomycin | |
| 653 | 4 | _aVinblastine | |
| 700 | 0 |
_aEmad Hamada , _eSupervisor |
|
| 700 | 0 |
_aFarook Haggag , _eSupervisor |
|
| 700 | 0 |
_aWafaa Hassan Elmetnawy , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c40209 _d40209 |
||